Ahead of an advisory committee meeting, the agency contradicted some of what the company had said ab...
BUSINESS NEWS
July 27, 2026
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Ahead of an advisory committee meeting, the agency contradicted some of what the company had said about the benefits of its rare disease treatment.
Ahead of an advisory committee meeting, the agency contradicted some of what the company had said about the benefits of its rare disease treatment.
Author: STAT
Read Original Article
